On June 4, 2026, the U.S. Food and Drug Administration cleared Masimo Corporation's Radius VSM and Accessories through the 510(k) premarket-notification pathway, assigning it clearance number K254209. The decision is recorded as a Traditional 510(k) found Substantially Equivalent to a legally marketed predicate device. The submission was received on December 29, 2025, putting the review cycle at just over five months.
What makes this clearance worth a second look is not the device's novelty but its classification. The FDA filed Radius VSM under product code MHX, regulation number 870.1025, in the Cardiovascular advisory panel as a Class II device. The generic device type recorded for that code, taken verbatim from the FDA record, reads as follows.
"Monitor, Physiological, Patient(With Arrhythmia Detection Or Alarms)"— FDA device classification (openFDA), product code MHX, source
That phrasing matters. A great deal of Masimo's consumer-facing reputation rests on pulse oximetry and the litigation it has waged over wrist-worn sensing. But MHX is a multiparameter physiological monitor category that explicitly anticipates arrhythmia detection or alarms — the kind of continuous, cardiac-aware surveillance historically done at a bedside, not on a wrist. Radius VSM is Masimo's tetherless, body-worn vital-signs platform, and clearing it into the 870.1025 regulation is a statement about the rigor the company is willing to subject its untethered sensing to.
Why the product code is the story
In 510(k) analysis, the product code is the most compact summary of what the FDA believes a device is. It binds the device to a regulation, a Class, an advisory panel, and a set of special controls. Radius VSM's MHX code sits under 21 CFR 870.1025 and the Cardiovascular panel, which is a meaningfully different posture than a simple pulse-oximeter clearance would carry. The distinction tells a strategist that Masimo is positioning Radius VSM not as a single-parameter sensor but as a consolidated monitoring node — one whose alarms and arrhythmia logic the agency has reviewed.
The Traditional 510(k) route, as opposed to a Special or Abbreviated submission, also signals the breadth of the change Masimo asserted relative to its predicate. A Traditional submission is the most comprehensive of the three formats and is typically used when a device's technological characteristics differ enough from the predicate that the sponsor must demonstrate substantial equivalence across a fuller set of performance data. The five-month turnaround from a December 29, 2025 receipt to a June 4, 2026 decision is brisk for a Traditional filing in a cardiovascular category, which suggests the predicate comparison was clean.
The consumer-tech read
For readers who follow Masimo through the lens of its consumer-wearables ambitions and its long-running sensor disputes, the Radius VSM clearance is a reminder that the company's center of gravity remains clinical-grade monitoring. A wrist or body-worn device cleared as an arrhythmia-aware physiological monitor is a far heavier regulatory object than a wellness gadget that estimates heart rate. It carries alarm obligations, predicate-tied performance claims, and a Class II special-controls burden.
That heaviness is exactly the competitive moat. The same arrhythmia-detection framing that consumer-electronics companies have spent years trying to earn for their watches is, for Masimo, table stakes in the category it already inhabits. When a tetherless monitor clears under MHX rather than a lighter wellness code, it can make medical-grade alarm claims that a fitness wearable cannot. That is the asymmetry worth tracking as the line between clinical monitors and consumer wearables continues to blur.
Where this fits in Masimo's portfolio map
Read as a landscape data point rather than a one-off, the Radius VSM clearance fits a recognizable pattern: Masimo has been steadily extending its monitoring franchise from the bedside outward toward ambulatory and untethered form factors, while keeping each new product anchored to a clinical product code rather than a wellness one. The 'VSM' — vital-signs monitor — naming convention signals a multiparameter device, and clearing it under MHX rather than a discrete oximetry or heart-rate code is consistent with a strategy of consolidating multiple physiological parameters and their alarms into a single cleared platform.
The strategic logic is straightforward. A body-worn, multiparameter monitor that can make arrhythmia and alarm claims is positioned to follow a patient out of the intensive-care bed and into the general ward, the step-down unit, and ultimately the home — without surrendering the clinical-grade claims that distinguish it from consumer wearables. Each clearance that lands in a clinical code rather than a wellness code widens the gap between what Masimo can assert and what a fitness-band maker can. For a portfolio analyst, the takeaway is that Masimo is competing on regulatory standing as much as on sensor performance, and Radius VSM extends that standing into a tetherless form factor.
What the record establishes — and what it does not
None of this is to overstate scope. A 510(k) clearance establishes substantial equivalence to a predicate — it is not a finding of safety and effectiveness in the way a PMA approval is, and it does not, on its own, tell us the predicate device or the specific performance claims Masimo made. Those live in the cleared 510(k) summary, which is the canonical record. What the openFDA entry does establish, verbatim and without inference, is the device name, the applicant, the June 4, 2026 decision date, the Substantially Equivalent determination, and the MHX classification that frames everything else.
The cleaner narrative will emerge when the full 510(k) summary publishes and names the predicate. If the predicate is a prior Radius-family device, this is an incremental platform extension; if it is a fixed bedside monitor, Masimo is asserting equivalence between a tetherless wearable and a hardwired clinical instrument — a more aggressive and more interesting claim. Either way, the classification is locked: as of June 4, 2026, Masimo holds a Class II clearance for an arrhythmia-aware physiological monitor in the form factor it has spent years defending in court. The regulatory record, not the marketing, is where that story is now anchored.